The United States has filed a complaint under the False Claims Act against AIMA Business and Medical Support, LLC (AIMA), a company that provides medical billing and compliance services, for allegedly submitting or causing the submission of false claims to Medicare for medically unnecessary genetic laboratory tests. The United States contends that from August 2018 through August 2019, AIMA billed Medicare Part B approximately $ 15,178,946.00 for genetic tests on behalf of Selecta, even though AIMA knew or should have known that the tests were not medically necessary and were not ordered by the beneficiary’s treating physician. Medicare does not cover the costs of genetic tests that are not reasonable and necessary for the diagnosis or treatment of illness. To be covered by Medicare, a diagnostic laboratory test, including a genetic test, must be ordered by the physician who is treating the beneficiary for a specific medical problem and who uses the results in the management of that problem. As a result of AIMA’s conduct, Selecta received Medicare funds to which it was not entitled and, correspondingly, paid AIMA for its services.